stockrow
Saturday 7 November 2026
Export PRTCY’s income statement to Excel — free account
PureTech Health PLC Sponsored ADR
PRTCY Healthcare Biotechnology
PureTech Health PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 3.50% from fiscal 2024.
16.34
0.39
−2.33%
Follow PRTCY
Alert me
PureTech Health PLC Sponsored ADR (PRTCY) P/E ratio
PureTech Health PLC Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 45.9× (August 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 36.9× | 4.63% |
| FY2020 | 35.3× | 68.71% |
| FY2020 | 20.9× | 0.00% |
| FY2019 | 20.9× | 0.00% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 45.9×
Ten-year median
0.0×
Current reading's percentile
81
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GYRE Gyre Therapeutics, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| OCS Oculis Holding AG compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| ARVN Arvinas, Inc. compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 2.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)